Aleix Prat points out the importance of the results presented during the ESMO 2017 Congress for the breast cancer community.
Angelo Di Leo explains that the MONARCH 3 study was designed to determine whether we can improve the activity of endocrine therapy by combining it with CDK4-6 inhibitor therapy in ER+/HER2- advanced breast cancer patients. As expected, the combination improves the efficacy both clinically and statistically, with an observed 46% decrease in risk of progression.
Paul Cottu shows in the NeoPAL study that endocrine therapy plus CDK4/6 inhibition is not better than neoadjuvant chemotherapy in luminal stage II/III ER+/HER2- breast cancer.
The ExteNet trial focuses on early-stage HER2+ breast cancer patients. Miguel Martin explains that the idea was to add neratinib to the standard chemotherapy plus trastuzumab therapy. The 5-year results confirm the overall benefit with neratinib. Further studies are needed to confirm if standard therapy should be completed with one-year neratinib for high-risk HR+ patients.
The LORELEI study tested the addition of a PIK3CA alpha inhibitor on top of endocrine therapy in post-menopausal ER+/HER2- early breast cancer patients. Cristina Saura reports that tumour response is increased with the combination. A larger phase III trial will be needed to tell us if this should change clinical practice.
236O_PR MONARCH 3: Abemaciclib as initial therapy for patients with HR+/HER2- advanced breast cancer
LBA9 – Letrozole and palbociclib versus 3rd generation chemotherapy as neoadjuvant treatment of luminal breast cancer. Results of the UNICANCER-NeoPAL study
ER+/HER2-negative early breast cancer (EBC)
149O – Neratinib after trastuzumab (T)-based adjuvant therapy in early-stage HER2+ breast cancer (BC): 5?year analysis of the phase III ExteNET trial
LBA10_PR – Primary results of LORELEI: a phase II randomized, double-blind study of neoadjuvant letrozole (LET) plus taselisib versus LET plus placebo (PLA) in postmenopausal patients (pts) with ER+/HER2-negative early breast cancer (EBC)
Produced by the European Society for Medical Oncology